

RECEIVED  
AUG 09 2002  
TECH CENTER 1600/2900U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENTDocket Number:  
10793/45Application Number  
10/032,423Filing Date  
December 31, 2001

Examiner

Art Unit  
1614

Invention Title

**Y17-ISOLATED MOLECULES COMPRISING  
EPITOPES CONTAINING SULFATED MOIETIES,  
ANTIBODIES TO SUCH EPITOPES, AND USES  
THEREOF**

Inventor(s)

**J. LAZAROVITS et al.**Address to:  
Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents &amp; Trademarks, Washington, D.C. 20231.

Date: August 2, 2002

Signature:

Kathryn M. Lumb, Reg. No. 46,885

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: Aug. 2, 2002

By:

Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
**10793/45**

SERIAL NO.  
**10/032,423**

APPLICANT(S) **LAZAROVITS et al.**

FILING DATE  
**December 31, 2001**

GROUP  
**1614**

TECH CENTER 1500/2900

AUG 09 2002

RECEIVED

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	INVENTORS NAME
	5,223,409	6/29/93	Ladner et al.
	5,403,484	4/4/95	Ladner et al.
	5,427,908	6/25/95	Dower et al.
	5,432,018	7/11/95	Dower et al.
	5,702,954	2/24/98	Hudziak et al.
	5,763,215	6/9/98	Blumberg et al.
	5,795,776	8/18/98	Fischer
	5,821,337	10/13/98	Carter et al.
	5,843,439	12/1/98	Anderson et al.
	5,945,304	8/31/99	Fischer

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
	WO 94/26787	11/24/94	PCT		
	WO 00/29004	5/25/00	PCT		
	EP 0 589 877	11/13/96	Europe		



## OTHER DOCUMENTS

RECEIVED  
AUG 09 2002  
TECH CENTER 1600/2900

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Altschul et al. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic-Acids Research, 1997, vol. 25, no. 17, pp. 3389-3402 ✓
	Bass, et al. "Hormone Phage: An enrichment method for variant proteins with altered binding properties", Proteins: Structure, Function and Genetics, 1990 vol. 8, pp. 309-314 ✓
	Caron et al., "Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-CD33) for the therapy of acute myelogenous leukemia", Cancer Supplement, Feb. 1, 1994, vol. 73, no. 3, pp.1049-1056 ✓
	Caron et al., "A Phase 1B trial of humanized monoclonal antibody M195 (Anti-CD33) in myeloid leukemia: specific targeting without immunogenicity" ✓
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands", Proc. Nat'l. Acad. Sci. USA, August 1990, vol. 87, pp. 6378-6382 ✓
	Devlin et al., "Random peptide libraries: a source of specific protein binding molecules", Science, vol 249, pp. 404-406 ✓
	Griffiths et al., "Isolation of high affinity human antibodies directly from large synthetic repertoires," EMBO Journal, 1994, vol. 13, no. 14, pp. 3245-3260 ✓
	Henkart, "Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules", Immunity, August 1984, vol. 1, pp. 343-346 ✓
	Holliger et al., " "Diabodies": small bivalent and bispecific antibody fragments", Proc. Nat'l. Acad. Sci. USA, July 1993, vol. 90, pp. 6444-6448 ✓
	Hudson et al., "High avidity scFv multimers: diabodies and triabodies", Journal of Immun. Methods, 1999, vol. 231, pp. 177-189 ✓
	Jarvik et al., "Epitope Tagging", Annu. Rev. Genet., 1998, vol. 32, pp. 601-618 ✓
	Jurcic et al., ABSTRACT #2528, Blood, 1992 (10 Suppl. Part 1-2) ✓
	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer", Protein Engineering, 1997, vol. 10, no. 4, pp. 423-433 ✓
	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, Dec. 6, 1990, vol. 348, pp. 552-554 ✓
	McGraw et al., "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias", Cancer Immunol. Immunotherapy, 1994, vol. 39, pp. 367-374 ✓
	Nissim et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO Journal, 1994, vol. 13, no. 3, pp. 692-698 ✓
	Scott et al., "Searching for peptide ligands with an epitope library", Science, July 27, 1990, vol. 249, pp. 386-390 ✓
	Sgouros et al. ABSTRACT #979, J. Nucl. Med. Vol. 38 (5 Suppl.) ✓
	Sievers et al., ABSTRACT #2246, Blood, vol. 90 (10 Suppl. 1 Part 1) ✓
	Smith, "Filamentous Fusion Phage: Novel expression vectors that displayed cloned antigens on the virion surface", Science, June 14, 1985, vol. 228, pp. 1315-1317 ✓
	Squier et al., "Cell-mediated cytotoxic mechanisms", Current Opinion in Immunology, 1994, vol. 6, pp. 447-452 ✓
	Sun et al., "Antitumour activity of a chimeric antibody against the leucocyte antigen CD48", Cancer Immunol. Immunotherapy, 2000, vol. 48, pp. 595-602 ✓
	Takebe et al., "Src Promoter: an efficient and versatile mammalian cDNA Expression System....", Molecular and Cellular Biology, Jan. 1988, vol. 8, no. 1, pp. 466-472 ✓
	Thompson et al. "A fully human antibody neutralising biologically active human TGFβ2 for use in therapy", J. of Immunol. Methods, 1999, vol. 227, pp. 17-26 ✓
	Tomlinson et al., The repertoire of human germline V <sub>H</sub> segments with different hypervariable loops", J. Mol. Biol., 1992, vol. 227, pp. 776-798 ✓

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	